ClinicalTrials.gg
RecruitingNCT04485871Updated Mar 12, 2026

Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids

An interventional study of Omega-3 fatty acids in Type 2 Diabetes, Inflammation and Insulin Sensitivity/Resistance, sponsored by Institut de Recherches Cliniques de Montreal. Recruiting at 1 site in Canada. Open to participants aged 45 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Institut de Recherches Cliniques de Montreal · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Dec 2019, registered Jul 2020).
  • Started Dec 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
45 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, none of them phase 3. omega-3 fatty acid · Diabetes Mellitus, Type 2.

Planned enrollment
10th of 14
48 · median 77
Started
2019
with 1 other
No phase
7 of 14
3 open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Institut de Recherches Cliniques de Montreal

Among the 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2, this one is the 10th largest by planned enrollment, is one of 2 that started in 2019, is one of 7 with no phase, and was the 10th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About omega-3 fatty acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 45 Years to 74 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Every 3 minutes a new case of diabetes is diagnosed in Canada, mostly type 2 diabetes (T2D) increasing the risk for heart disease. T2D and heart disease share many common risk factors such as aging, obesity and unhealthy lifestyle.

Paradoxically however, while lowering blood LDL, commonly known as "bad cholesterol", is protective against heart disease, research over the past 10 years have shown that the lower is blood LDL, the higher is the chance of developing T2D. This phenomena is happening whether blood LDL is lowered by a common drug against heart disease called Statins, or by being born with certain variations in genes, some of which are very common (\~80% of people have them).

To date, it is unclear why lowering blood LDL is associated with higher risk for diabetes, and whether this can be treated naturally with certain nutrients.

Investigators believe that lowering blood LDL by forcing LDL entry into the body tissue through their receptors promotes T2D. This is because investigators have shown that LDL entry into human fat tissue induces fat tissue dysfunction, which would promote T2D especially in subjects with excess weight.

On the other hand, investigators have shown that omega-3 fatty acids (omega-3) can directly treat the same defects induced by LDL entry into fat tissue. Omega-3 is a unique type of fat that is found mostly in fish oil.

Thus the objectives of this clinical trial to be conducted in 48 subjects with normal blood LDL are to explore if:

  1. Subjects with higher LDL receptors and LDL entry into fat tissue have higher risk factors for T2D compared to subjects with lower LDL receptors and LDL entry into fat tissue
  2. 6-month supplementation of omega-3 from fish oil can treat subjects with higher LDL receptors and LDL entry into fat tissue reducing their risk for T2D.

This study will thus explore and attempt to treat a new risk factor for T2D using an inexpensive and widely accessible nutraceutical, which would aid in preventing T2D in humans.

Read the detailed description

Type 2 (T2D) and cardiovascular disease (CVD) share many risk factors, whose accumulation over years lead to disease onset. However, while lowering plasma low-density lipoprotein cholesterol (LDLC) is cardio-protective, novel evidence over the past 10 years established a role for common LDLC-lowering variants and widely used hypocholesterolemic Statins in higher risk for T2D. This diminishes the cardio-protective role of low plasma LDLC. As these conditions decrease plasma LDLC by increasing tissue-uptake of LDL, a role for LDL receptor (LDLR) pathway was proposed. However underlying mechanisms fueling higher risk for T2D with upregulated LDLR pathway, and nutritional approaches to treat them are unclear.

The central hypothesis examined in this trial is that upregulating receptor-mediated uptake of LDL on white adipose tissue provokes the activation of an innate immunity pathway (the Nucleotide-binding domain and Leucine-rich repeat Receptor, containing a Pyrin domain 3 (NLRP3) inflammasome) leading to the accumulation of risk factors for T2D in subjects with normal plasma LDLC. This can be treated by 6-month supplementation of omega-3 fatty acids (omega-3).

To examine this hypothesis in vivo, ex vivo and in vitro, a clinical trial in conjunction with mechanistic basic research studies have been initiated at the Montreal Clinical Research Institute (IRCM). Forty eight volunteers will be recruited through advertisements in French/English newspapers and online (e.g. Google, Facebook) and placed on a 6-month supplementation of 3.6 g omega-3 per day. Participants will be stratified into 2 groups (N=24/group) with higher and lower white adipose tissue surface-expression LDL receptors (LDLR and CD36) using median plasma PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) per sex. Plasma PSCK9 will be used as investigators have shown that it is negatively associated with white adipose tissue surface-expression of LDLR and CD36.

The duration of this study is about 8 months (33 weeks) divided into 5 parts:

A. Screening and evaluation of eligibility for the study

B. Weight stabilisation (+/- 2 kg change over 4 weeks) and confirmation of eligibility after a medical examination by IRCM physician collaborators.

C. Baseline testing over 2 days (1- 4 weeks apart) to assess participants risk factors for T2D: white adipose tissue NLRP3 inflammasome activity, white adipose tissue physiology and function (ex vivo after a subcutaneous needle biopsy), systemic inflammation, dietary fat clearance (after a high fat meal), and insulin secretion and sensitivity (by gold-standard Botnia clamp technique). Participants will also be phenotyped for body composition (by dual energy x-ray absorptiometry), resting energy expenditure (by indirect calorimetry), dietary intake (by 3-day dietary journals) and physical activity level (by a questionnaire).

D. 24-week intervention with omega-3 fatty acid supplementation (3.6 g eicosapentaenoic acid (EPA) and docosahexaenoic (DHA), 2:1)

E. Post intervention testing starting over 2 days (1- 4 weeks apart) to assess risk factors for T2D that were measured at baseline.

Investigators hypothesize that subjects with low plasma PCSK9 (i.e. with higher white adipose tissue LDLR and CD36) will have higher risk factors for T2D at baseline and that the omega-3 intervention will eliminate group-differences in these risk factors.

03

Conditions studied

  • Type 2 Diabetes
  • Inflammation
  • Insulin Sensitivity/Resistance
  • Fatty Acids, Omega-3

Keywords

  • Proprotein Convertase Subtilisin / kexin Type 9 (PCSK9)
  • NLRP3 inflammasome
  • Eicosapentaenoic acid (EPA)
  • Docosahexaenoic acid (DHA)
  • White adipose tissue
  • Fat metabolism
  • ApoB-lipoproteins
  • LDL receptors (LDLR)
  • Cluster of differentiation 36 (CD36)
04

Who can participate

Ages eligible
45 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Men and women:

  • Having a (BMI= 25-40 kg/m2)
  • Aged between 45 and 74 years
  • Having confirmed menopausal status (FSH ≥ 30 U/l)
  • Non-smoker
  • Sedentary (less than 2 hours of structured physical exercise (ex: sports club) per week)
  • Low alcohol consumption: less than 2 alcoholic drinks/day

Exclusion criteria

Exclusion Criteria:

  • Plasma LDL cholesterol > 3.5 mmol/L (i.e. > 75th percentile in a Canadian population).
  • Elevated risk of cardiovascular disease (≥ 20% of calculated Framingham Risk Score) who would require immediate medical intervention by lipid-lowering agents.
  • Prior history of cardiovascular events (like stroke, , myocardial infarction, angina, heart failure…)
  • Systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg
  • Type 1 or 2 diabetes or fasting glucose > 7.0 mmol/L
  • Prior history of cancer within the last 3 years
  • Thyroid disease - untreated or unstable
  • Anemia - \< 120 g/L
  • Renal dysfunction or plasma creatinine > 100 µmol/L
  • Hepatic dysfunction - /ALT > 3 times normal limit
  • Blood coagulation problems (i.e. bleeding predisposition)
  • and chronic inflammatory disease (i.e. celiac, inflammatory bowel, Graves, multiple sclerosis, psoriasis, rheumatoid arthritis, and lupus).Known history of difficulties accessing a vein
  • Claustrophobia
  • Sleep apnea
  • Seizures
  • Concomitant medications: Hormone replacement therapy (except thyroid hormone at a stable dose), systemic , anti-psychotic medications and psycho-active medication, anticoagulant or anti-aggregates treatment (Aspirin, NSAIDs, warfarin, coumadin..), adrenergic agonist, anti-hypertensive drugs, weight-loss medication, lipid lowering medication
  • Known substance abuse
  • Already taking more than 250 mg of omega-3 supplements (EPA/DHA) per day
  • Allergy to seafood or fish
  • Allergy to Xylocaine
  • Unable to eat the components of the high fat meal (croissant, cheese, bacon, brownies)
  • None compliance to the study requirements (i.e. not being fasting) or cancellation of the same scheduled testing visit more than once.
  • Lack of time to participate in the full length of the study (33 weeks)
  • Have exceeded the annual total allowed radiation dose (like X-ray scans and/or tomography in the previous year or in the year to come) according to the physician's judgement.
  • All other medical or psychological conditions deemed inappropriate according to the physician
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Omega-3 fatty acids

    3.6 g EPA:DHA / day (2:1)

    Dietary Supplement: Omega-3 fatty acids

Interventions

  • Dietary supplementOmega-3 fatty acidStudies of Omega-3 fatty acidOmega-3 fatty acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)

    Also known as: Triple Strength Omega-3 from Webber Naturals

06

What researchers measure

Primary outcomes

  1. Fasting white adipose tissue NLRP3 inflammasome activation

    White adipose tissue medium accumulation of interleukin 1 beta (IL-1β) ex vivo over 4 hours (pg/mg tissue by AlphaLISA)

    Time frame: Baseline

  2. Fasting white adipose tissue NLRP3 inflammasome activation

    White adipose tissue medium accumulation of interleukin 1 beta (IL-1β) ex vivo over 4 hours (pg/mg tissue by AlphaLISA)

    Time frame: At 24 weeks

Secondary outcomes

  1. Fasting plasma PCSK9 concentration

    Plasma PCSK9 (g/L by ElISA kit)

    Time frame: Baseline

  2. Fasting plasma PCSK9 concentration

    Plasma PCSK9 (g/L by ElISA kit)

    Time frame: At 24 weeks

  3. White adipose tissue receptors for apoB-lipoproteins

    Fasting and 4 hour-postprandial change in white adipose tissue surface-expression LDLR and CD36 (% of control by immunohistochemistry in white adipose tissue slides)

    Time frame: Baseline

  4. White adipose tissue receptors for apoB-lipoproteins

    Fasting and 4 hour-postprandial change in white adipose tissue surface-expression LDLR and CD36 (% of control by immunohistochemistry in white adipose tissue slides)

    Time frame: At 24 weeks

  5. White adipose tissue inflammation profile

    Fasting and 4 hour-postprandial change in NLRP3 inflammasome related inflammatory parameters; including gene expression of IL1B, NLRP3 and ADGRE1 (by RT-PCR) and secretion of IL-1β and IL-1Ra (per mg tissue by AlphaLISA)

    Time frame: Baseline

  6. White adipose tissue inflammation profile

    Fasting and 4 hour-postprandial change in NLRP3 inflammasome related inflammatory parameters; including gene expression of IL1B, NLRP3 and ADGRE1 (by RT-PCR) and secretion of IL-1β and IL-1Ra (per mg tissue by AlphaLISA)

    Time frame: At 24 weeks

  7. White adipose tissue function ex vivo

    Fasting and 4 hour postprandial change in situ lipoprotein lipase activity (nmol 3H-triglyceride/mg tissue)

    Time frame: Baseline

  8. White adipose tissue function ex vivo

    Fasting and 4 hour postprandial change in situ lipoprotein lipase activity (nmol 3H-triglyceride/mg tissue)

    Time frame: At 24 weeks

  9. Postprandial fat metabolism

    Area under the 6 hour time curve of plasma triglycerides (mmol/hour) after a high-fat meal (66% fat)

    Time frame: Baseline

  10. Postprandial fat metabolism

    Area under the 6 hour time curve of plasma triglycerides (mmol/hour) after a high-fat meal (66% fat)

    Time frame: At 24 week

  11. Systemic inflammation

    Fasting and 4 hour postprandial change in plasma inflammatory parameters including IL-1Ra and IL-1β (pg/mL by AlphaLISA)

    Time frame: Baseline

  12. Systemic inflammation

    Fasting and 4 hour postprandial change in plasma inflammatory parameters including IL-1Ra and IL-1β (pg/mL by AlphaLISA)

    Time frame: At 24 weeks

  13. Disposition index

    Calculated as glucose-induced insulin secretion (uU/mL/min) multiplied by insulin sensitivity (glucose infusion rate mg/kg/min) measured by Botnia clamp

    Time frame: Baseline

  14. Disposition index

    Calculated as glucose-induced insulin secretion (uU/mL/min) multiplied by insulin sensitivity (glucose infusion rate mg/kg/min) measured by Botnia clamp

    Time frame: At 24 weeks

  15. Fatty acid profile in red blood cell phospholipid fraction

    (As μmol/L by gas chromatography mass spectrometry)

    Time frame: Baseline

  16. Fatty acid profile in red blood cell phospholipid fraction

    (As μmol/L by gas chromatography mass spectrometry)

    Time frame: At 24 weeks

  17. Body composition

    Fat and lean body mass (as kg by dual energy x-ray absorptiometry)

    Time frame: Baseline

  18. Body composition

    Fat and lean body mass (as kg by dual energy x-ray absorptiometry)

    Time frame: At 24 weeks

  19. Energy intake

    (Average of 3 day energy intake as kcal/day collected by 3-day dietary records)

    Time frame: Baseline

  20. Energy intake

    (Average of 3 day energy intake as kcal/day collected by 3-day dietary records)

    Time frame: At 24 weeks

  21. Physical activity

    (using Godin Leisure Time Exercise Questionnaire)

    Time frame: Baseline

  22. Physical activity

    (using Godin Leisure Time Exercise Questionnaire)

    Time frame: At 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bissonnette S, Salem H, Wassef H, Saint-Pierre N, Tardif A, Baass A, Dufour R, Faraj M. Low density lipoprotein delays clearance of triglyceride-rich lipoprotein by human subcutaneous adipose tissue. J Lipid Res. 2013 May;54(5):1466-76. doi: 10.1194/jlr.P023176. Epub 2013 Feb 17. PubMed 23417739 ↗
  • Wassef H, Bissonnette S, Saint-Pierre N, Lamantia V, Cyr Y, Chretien M, Faraj M. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans. J Clin Lipidol. 2015 Sep-Oct;9(5):664-75. doi: 10.1016/j.jacl.2015.06.012. Epub 2015 Jul 2. PubMed 26350813 ↗
  • Lamantia V, Bissonnette S, Wassef H, Cyr Y, Baass A, Dufour R, Rabasa-Lhoret R, Faraj M. ApoB-lipoproteins and dysfunctional white adipose tissue: Relation to risk factors for type 2 diabetes in humans. J Clin Lipidol. 2017 Jan-Feb;11(1):34-45.e2. doi: 10.1016/j.jacl.2016.09.013. Epub 2016 Oct 3. PubMed 28391908 ↗
  • Skeldon AM, Faraj M, Saleh M. Caspases and inflammasomes in metabolic inflammation. Immunol Cell Biol. 2014 Apr;92(4):304-13. doi: 10.1038/icb.2014.5. Epub 2014 Feb 11. PubMed 24518981 ↗
  • Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 Feb 27;375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6. Epub 2010 Feb 16. PubMed 20167359 ↗
  • Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 Aug 11;380(9841):565-71. doi: 10.1016/S0140-6736(12)61190-8. PubMed 22883507 ↗
  • Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, Luan J, Ardanaz E, Arriola L, Balkau B, Boeing H, Deloukas P, Forouhi NG, Franks PW, Grioni S, Kaaks R, Key TJ, Navarro C, Nilsson PM, Overvad K, Palli D, Panico S, Quiros JR, Riboli E, Rolandsson O, Sacerdote C, Salamanca EC, Slimani N, Spijkerman AM, Tjonneland A, Tumino R, van der A DL, van der Schouw YT, McCarthy MI, Barroso I, O'Rahilly S, Savage DB, Sattar N, Langenberg C, Scott RA, Wareham NJ. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. JAMA. 2016 Oct 4;316(13):1383-1391. doi: 10.1001/jama.2016.14568. PubMed 27701660 ↗
  • Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh GK, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Liu T, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott R, Luan J, Bobak M, Malyutina S, Pajak A, Kubinova R, Tamosiunas A, Pikhart H, Husemoen LL, Grarup N, Pedersen O, Hansen T, Linneberg A, Simonsen KS, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Kirchner HL, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H; LifeLines Cohort study group; Christen T, Mook-Kanamori DO, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dorr M, Lerch MM, Volker U, Volzke H, Ward J, Pell JP, Smith DJ, Meade T, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Balkau B, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Ridker PM, Chasman DI, Reiner AP, Lange LA, Ritchie MD, Asselbergs FW, Casas JP, Keating BJ, Preiss D, Hingorani AD; UCLEB consortium; Sattar N. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2017 Feb;5(2):97-105. doi: 10.1016/S2213-8587(16)30396-5. Epub 2016 Nov 29. PubMed 27908689 ↗
  • Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016 Dec 1;375(22):2144-2153. doi: 10.1056/NEJMoa1604304. PubMed 27959767 ↗
  • Faraj M. LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue. J Biomed Res. 2020 Mar 12;34(4):251-259. doi: 10.7555/JBR.34.20190124. PubMed 32701068 ↗
  • Cyr Y, Bissonnette S, Lamantia V, Wassef H, Loizon E, Ngo Sock ET, Vidal H, Mayer G, Chretien M, Faraj M. White Adipose Tissue Surface Expression of LDLR and CD36 is Associated with Risk Factors for Type 2 Diabetes in Adults with Obesity. Obesity (Silver Spring). 2020 Dec;28(12):2357-2367. doi: 10.1002/oby.22985. Epub 2020 Oct 11. PubMed 33043593 ↗
  • Cyr Y, Lamantia V, Bissonnette S, Burnette M, Besse-Patin A, Demers A, Wabitsch M, Chretien M, Mayer G, Estall JL, Saleh M, Faraj M. Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome. Physiol Rep. 2021 Feb;9(3):e14721. doi: 10.14814/phy2.14721. PubMed 33527668 ↗

Individual participant data

Plan to share: No — Frozen plasma and white adipose tissue samples (when sufficient) can be made available for analysis by other investigators. However data statistical analyses incorporating complete IPD must be conducted by the research team of Dr May Faraj as per subject consent form.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for May 2027, 89 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 89 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2020
First posted
Jul 24, 2020
StartActual
Dec 19, 2019
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04485871
Lead sponsor
Institut de Recherches Cliniques de Montreal
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
May Faraj, PDt, PhD (Professor, Institut de Recherches Cliniques de Montreal) — Principal investigator
First posted
Jul 24, 2020
Start date
Dec 19, 2019
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Mar 12, 2026

Study contacts

Justine Fricher, MSc
Contact
justine.fricher@ircm.qc.ca
514-987-5500 ext. 3260
Rianne Mahiout, BSc
Contact
rianne.mahiout@ircm.qc.ca
514-987-5500 ext. 3360
May Faraj, PDt, PhD
principal investigator · Montreal Clinical Research Institute/ University of Montreal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omega-3 fatty acid

Start the discussion